CM
NBIX icon

Caption Management’s Neurocrine Biosciences NBIX Stock Holding History

Caption Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
+8,900
New +$1.18M 0.01% 974
2025
Q2 		– Sell
-130,800
Closed -$15M – 1740
2025
Q1 		$14.5M Buy
+130,800
New +$16.6M 0.14% 132
2024
Q4 		– Sell
-2,900
Closed -$334K – 1706
2024
Q3 		$334K Sell
2,900
-45,700
-94% -$6.27M 0.01% 999
2024
Q2 		$6.69M Buy
48,600
+28,400
+141% +$3.89M 0.1% 208
2024
Q1 		$2.79M Buy
+20,200
New +$2.76M 0.04% 448
2023
Q3 		– Sell
-9,000
Closed -$948K – 1433
2023
Q2 		$849K Buy
+9,000
New +$879K 0.02% 700
2022
Q2 		– Sell
-21,000
Closed -$1.94M – 1695
2022
Q1 		$1.97M Buy
21,000
+8,762
+72% +$743K 0.02% 761
2021
Q4 		$1.04M Sell
12,238
-11,594
-49% -$1.07M 0.01% 1033
2021
Q3 		$2.29M Buy
23,832
+21,260
+827% +$2.01M 0.03% 714
2021
Q2 		$250K Sell
2,572
-4,037
-61% -$387K ﹤0.01% 1154
2021
Q1 		$643K Sell
6,609
-9,391
-59% -$985K 0.01% 764
2020
Q4 		$1.53M Sell
16,000
-4,900
-23% -$473K 0.04% 508
2020
Q3 		$2.01M Sell
20,900
-28,989
-58% -$3.35M 0.05% 423
2020
Q2 		$6.09M Buy
49,889
+10,989
+28% +$1.21M 0.2% 134
2020
Q1 		$3.37M Buy
38,900
+23,700
+156% +$2.32M 0.19% 155
2019
Q4 		$1.63M Buy
+15,200
New +$1.59M 0.05% 393
2019
Q2 		– Sell
-25,000
Closed -$2.05M – 776
2019
Q1 		$2.2M Buy
+25,000
New +$2.09M 0.12% 223

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's NBIX Position: Q1 2026 in Review

Caption Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 8,900 shares worth $1.17M. The stake represents 0.01% of the portfolio and ranks #974 among its holdings. This is a return to the name: Caption Management previously reported a position in NBIX as recently as Q1 2025.

Caption Management first reported a position in NBIX in Q1 2019 and has held it in 17 quarters since. The position peaked at $14.5M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Caption Management held 8,900 shares of Neurocrine Biosciences worth $1.17M as of Q1 2026.
  • Neurocrine Biosciences was a new Caption Management position in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of Caption Management's portfolio in Q1 2026, its #974 holding.
  • Caption Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 17 quarters since.
  • Caption Management's Neurocrine Biosciences position peaked at $14.5M in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.